More prospective cohort studies with larger sample sizes and expanded anti-MAA antibody profiling (e.g., multiple isotypes and MAA-modified tissue-specific proteins and epitopes) are needed to fully assess the diagnostic and prognostic potential of anti-MAA antibodies in RA. This evidence concerns the gene NAA10 and rheumatoid arthritis.